Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HSD17B1 | P14061 | 16/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 15/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9997049 | 0.80 | PFKFB3 (0.58) | HSD17B1HSD17B2MCL1 | |
| SCHEMBL14018653 | 0.80 | TDP1 (0.53) | MAPTLMNATDP1HSD17B1HSD17B2 | |
| SCHEMBL3007570 | 0.79 | HSD17B1 (0.49) | HSD17B1HSD17B2ALDH1A1HPGD | |
| SCHEMBL15056014 | 0.79 | HSD17B1 (0.53) | HSD17B1HSD17B2 | |
| SCHEMBL8281131 | 0.77 | TDP1 (0.64) | MAPTLMNATDP1HSD17B1HSD17B2 | |
| SCHEMBL3471160 | 0.76 | HSD17B1 (0.60) | MAPTLMNAHSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL3007092 | 0.75 | HSD17B1 (0.60) | MAPTLMNAHSD17B1HSD17B2FYN | |
| SCHEMBL8281114 | 0.74 | TDP1 (0.64) | MAPTLMNATDP1ALDH1A1MAPK1 | |
| SCHEMBL14018727 | 0.74 | MAPT (0.64) | MAPTLMNATDP1ALDH1A1HPGD | |
| SCHEMBL8279498 | 0.74 | MAPT (0.60) | MAPTLMNATDP1FYNALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | BIOTIE THERAPIES CORPORATION (FI) | 2008-10-16 | — | — | US | disclosed |
| WO-2005090298-A1 | SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255169-A1 | 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread | NR1I2, ITGA2, ITGB2 | MAPT 4739/4885LMNA 3369/4885TDP1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.